The Economics of Personalized Medicine
Can companies investing in innovative liquid biopsy technologies continue to ignore healthcare economics?
Ilan Danieli |
As an economics-trained executive of a cancer diagnostics company, I often struggle to rationalize the business model and economic considerations of our healthcare environment. Most people are familiar with the statistic (ostensibly) stating that 90 percent of a patient’s healthcare costs are incurred during the last six months of their life. We also know that the value derived from that spend – as measured by patient quality of life during that period – is often questionable. Yet companies continue to develop products and services that feed into and worsen that statistic, rather than attempting to improve it. We routinely hear of a new “miraculous” chemotherapy drug that costs US$100,000 per regimen and extends patients’ lives by an average of about three months. This leads us to a complex question: How do we balance clinical, emotional, moral, and economic considerations? Are we, as a society, directing our resources in a sensible manner?
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine